# T cell-mediated control of dermal fibroblast gene programs and dysfunction in scleroderma

> **NIH NIH R21** · BENAROYA RESEARCH INST AT VIRGINIA MASON · 2024 · $259,950

## Abstract

PROJECT SUMMARY/ABSTRACT
Systemic sclerosis (SSc), also known as scleroderma, is an idiopathic disease of the connective tissue
characterized by fibrosis of the skin and underlying organs. It has the highest mortality of all rheumatic conditions
and no cure. T cells predominate in lesional SSc skin and patient serum is enriched in T cell cytokines.
Immunosuppression that limits T cell function can decrease symptoms of fibrosis, but also increases patient
susceptibility to infection. An array of functionally distinct T cells are in close-contact with fibroblasts in healthy
skin, and dysregulated T cell-fibroblast crosstalk is thought to be a major driver of disease pathology. However,
while T cells are implicated in SSc progression, no studies have performed a rigorous mechanistic dissection of
T cell-directed changes to fibroblast gene programs in healthy and fibrotic skin. We previously identified a novel
population of cutaneous CD4+CLA+CD103+ T cells in the blood and skin that co-produce IL-22 and IL-13
implicating a role in skin homeostasis. We now find that the frequency of these and other cutaneous T cells are
altered in SSc, though their function in affected patient skin remains unexplored. Our novel preliminary data
show that different cutaneous T cell populations promote distinct fibroblast gene signatures and demonstrate a
strong CD103+ T cell-dependent effect on a newly identified SSc-associated fibroblast subset. We therefore
hypothesize that CD103+ T cell activity is essential for fibroblast homeostasis at the steady state and that normal
T cell-fibroblast interactions are disrupted in SSc, leading to fibroblast dysfunction. This proposal will use single-
cell spatial transcriptomics and innovative organotypic skin culture to fill critical knowledge gaps and overcome
existing technical hurdles in the field. Completion of these aims will build a foundation for the generation of
exciting new hypothesis and will advance a novel organotypic culture model with the potential to recapitulate in
vivo fibroblast heterogeneity associated with disease and tissue dysfunction.

## Key facts

- **NIH application ID:** 10952762
- **Project number:** 1R21AI185642-01
- **Recipient organization:** BENAROYA RESEARCH INST AT VIRGINIA MASON
- **Principal Investigator:** Peter A Morawski
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $259,950
- **Award type:** 1
- **Project period:** 2024-06-12 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10952762

## Citation

> US National Institutes of Health, RePORTER application 10952762, T cell-mediated control of dermal fibroblast gene programs and dysfunction in scleroderma (1R21AI185642-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10952762. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*